LGD-4033, also known as Ligandrol, is a selective androgen receptor modulator (SARM) that was first developed in 2004 by Ligand Pharmaceuticals. SARMs are a class of compounds that bind to the androgen receptor, which is a protein that plays a role in muscle growth and development. However, SARMs are more selective than testosterone, meaning that they have a greater effect on muscle tissue and less of an effect on other tissues, such as the prostate and liver.
LGD-4033 was initially developed as a potential treatment for muscle wasting in patients with cancer and other diseases. However, it has also been shown to be effective at promoting muscle growth and strength in healthy individuals.
In 2010, LGD-4033 entered Phase 1 clinical trials for the treatment of muscle wasting in patients with cancer. The results of the Phase 1 trial were positive, and LGD-4033 entered Phase 2 clinical trials in 2013.
The Phase 2 trials of LGD-4033 were also positive, and the drug entered Phase 3 clinical trials in 2016. LGD-4033 is currently in Phase 3 clinical trials for the treatment of muscle wasting in patients with cancer and other diseases.
In addition to its potential for the treatment of muscle wasting, LGD-4033 is also being investigated for the treatment of other conditions, such as osteoporosis, sarcopenia, and cachexia.
Here is a timeline of the key events in the history of LGD-4033:
- 2004: LGD-4033 is developed by Ligand Pharmaceuticals.
- 2010: LGD-4033 enters Phase 1 clinical trials for the treatment of muscle wasting in patients with cancer.
- 2013: LGD-4033 enters Phase 2 clinical trials for the treatment of muscle wasting in patients with cancer.
- 2016: LGD-4033 enters Phase 3 clinical trials for the treatment of muscle wasting in patients with cancer and other diseases.
LGD-4033 is still under development, but it has shown promise as a potential treatment for a variety of conditions. More research is needed to confirm its long-term safety and efficacy.
It is important to note that LGD-4033 is not approved for human use by the FDA.
